| Literature DB >> 22398036 |
David Boutolleau1, Ana Canestri, Sonia Burrel, Marc Wirden, Sophie Seang, Cyril Clavel-Osorio, Anne-Geneviève Marcelin, Christine Katlama, Henri Agut.
Abstract
Foscarnet (FOS) is a pyrophosphate analogue that inhibits both cytomegalovirus (CMV) and human immunodeficiency virus (HIV) replication. We describe herein the emergence of CMV resistance to FOS in a 54-year-old man receiving FOS salvage therapy because of multidrug-resistant HIV-1 infection. Oral valganciclovir (VGCV) treatment allowed subsequently the improvement of FOS-resistant CMV infection.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22398036 DOI： 10.1016/j.jcv.2012.02.008
Source DB: PubMed Journal: J Clin Virol ISSN： 1386-6532 Impact factor: 3.168